A Home-based e-Health Intervention in the Elderly: MOVI-ageing

Change in Health-related quality of life

SF-12 test

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Depression, anxiety and stress

Yesavage's 15-item GDS questionnaire

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Psychological well-being

Scale proposed by Ryff and translated and validated in Spanish by Diaz et al

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Physical activity

Axivity 6axes accelerometers (Axivity LTd. ) for seven consecutive days

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase

Change in Physical function

Short Portable Physical Battery scale

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Concern about falls

Falls Efficacy Scale International (FES-I)

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Weight

the mean of two measurements (using a scale (Seca® 861) with the participant barefoot and lightly clothed.

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Height

the mean of two measurements with a wall-mounted stadiometer (Seca® 222), with the participant barefoot and in an upright position while the sagittal midline of the back touches the vertical bar.

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Body mass index (BMI)

as weight (kg)/height2 (m2).

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Waist circumference

the mean of three measurements using a flexible tape measure at the midpoint between the last rib and the iliac crest at the end of a normal exhalation.

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Body fat percentage

the mean of two measurements using an eight-electrode Tanita® Segmental-418 bioimpedance system (Tanita Corp. Tokyo, Japan).

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Body composition by densitometry

With the DXA

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase

Change in HbA1c

using the ADAMS A1c HA-8180V analyzer (Menarini Diagnostics®), a method certified by the NGSP (National Glycohemoglobin Standardization Program) and the IFCC (International Federation of Clinical Chemistry and Laboratory Medicine).

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase

Change in Pulse wave velocity

with the SphygmoCor system (AtCor Medical Pty Ltd Head Office, West Ryde, Australia).

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase

Change in Fasting plasma glucose, apolipoproteins A1 and B, insulin ultrasensitive protein C and endothelial glycocalyx (syndecan-1, syndecan-4 and heparan sulfate proteins)

with the Abbott® Cobas 8000 Roche Diagnostics® system.

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase

Change in Endothelial function

with the ENDO-PAT.

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase

Change in 24-hour blood pressure

with the MAPA Mobil-O-graph.

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase

Change in Educational level

measured as the maximum level of education attained by each participant, classifying them as: cannot read or write, no studies, incomplete primary studies, primary studies, school graduate studies, higher baccalaureate studies, medium university studies, or higher university studies.

Time frame: At baseline of the 12 weeks intervention in the 2nd phase

Change in Adherence to the Mediterranean diet

with the Mediterranean Diet Adherence Screener (MEDAS) questionnaire

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Sleep habits and quality of sleep

with the Pittsburgh Sleep Quality Index (PSQI)

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase

Change in Comorbidities

with the Charlson comorbidity index.

Time frame: At baseline of the 12 weeks intervention in the 2nd and 3rd phase

Change in Attention

Using the Flanker Task test

Time frame: At baseline of the 12 weeks intervention in the 2nd and 3rd phase

Change in Working memory

Using the AWMA (Automated Working Memory Assessment) test

Time frame: At baseline of the 12 weeks intervention in the 2nd and 3rd phase

Change in Cognitive flexibility

Using the DCCS (Dimension Change Card Sort) test

Time frame: At baseline of the 12 weeks intervention in the 2nd and 3rd phase

Change in radial augmentation rate (rAIx)

with the SphygmoCor system (AtCor Medical Pty Ltd Head Office, West Ryde, Australia).

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase

Change in central augmentation rate (cAIx)

with the SphygmoCor system (AtCor Medical Pty Ltd Head Office, West Ryde, Australia).

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase

apolipoproteins A1 and B

with the Abbott® Cobas 8000 Roche Diagnostics® system.

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase

insulin ultrasensitive protein C

with the Abbott® Cobas 8000 Roche Diagnostics® system.

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase

endothelial glycocalyx (syndecan-1, syndecan-4 and heparan sulfate proteins)

with the Abbott® Cobas 8000 Roche Diagnostics® system.

Time frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase